Novel excipient composition for maintaining long-term dispensing storage stability of bacteriophages
By using anhydrous sodium sulfate composition as an excipient during phage storage, the problem of reduced phage titer is solved, and its storage stability under high temperature and humid conditions is significantly improved, and the validity period of the product is extended.
Patent Information
- Application Number
- CN202380033998.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-15
- Filing Date
- 2023-04-14
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art has difficulty maintaining the stability of phages due to the decrease in productivity and product quality due to the reduction of titer during the long-term storage of phages.
The composition containing anhydrous sodium sulfate is used as an excipient to improve its storage stability under different temperature and humidity conditions by mixing with the phage.
The reduction in phage titer is significantly reduced, especially under high temperature and humid conditions, which extends the storage stability of phages and improves product productivity and quality.
Smart Images

Figure CN119032162A_ABST
Abstract
Description
Technical Field
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority based on Korean Patent Application No. 10-2022-0047176 filed on April 15, 2022, and the entire content of the corresponding Korean patent application document is incorporated as a part of this specification.
[0003] The present invention relates to a novel excipient composition for maintaining the long-term storage stability of bacteriophages and use thereof. Background Art
[0004] Foodborne diseases caused by foodborne bacteria have been recognized as one of the serious public health problems occurring worldwide. Therefore, in the food industry, it is important to provide consumers with not only delicious and nutritious food, but also safe food that is free of foodborne bacteria that may cause illness.
[0005] Bacteriophages are a type of virus that uses bacteria as host cells and does not show toxicity to humans because it only specifically binds to bacteria. Due to this feature, bacteriophages have been widely used in the clinical treatment of infections caused by bacteria, and have been used in particular as feed additives for preventing or suppressing livestock diseases (Korean Patent Publication No. 10-2021-0145038).
[0006] On the other hand, according to the production and distribution of phage products for feed additives, conventionally used excipients have problems of decreased productivity and product quality due to decreased phage titer during long-term storage. Therefore, in the case of long-term distribution of phage products for feed additives, it is necessary to study excipients for quality maintenance.
[0007] [Prior art]
[0008] (Patent Document 1) KR 10-2021-0145038A Summary of the invention
[0009] Technical issues
[0010] One embodiment of the present application provides a composition for improving the stability of bacteriophages, which comprises anhydrous sodium sulfate. The composition can be used to maintain and / or increase the long-term stability (eg, storage stability, etc.) of bacteriophages.
[0011] Another embodiment provides a composition comprising bacteriophage and anhydrous sodium sulfate. The composition can be a feed composition, a food composition, a pharmaceutical composition or an antibacterial composition.
[0012] Other embodiments provide a method for improving the stability of bacteriophages, comprising mixing bacteriophages and a composition comprising anhydrous sodium sulfate for improving the stability of bacteriophages.
[0013] Other embodiments provide a use of anhydrous sodium sulfate for improving the stability of bacteriophages or for preparing a composition for improving the stability of bacteriophages.
[0014] Other embodiments provide a use of a bacteriophage and anhydrous sodium sulfate for preparing a feed composition, a food composition, a pharmaceutical composition or an antibacterial composition.
[0015] Other embodiments provide a use of a bacteriophage and a composition for improving the stability of a bacteriophage for preparing a feed composition, a food composition, a pharmaceutical composition or an antibacterial composition.
[0016] Technical Solution
[0017] One aspect provides a composition for improving the stability of bacteriophage, comprising anhydrous sodium sulfate.
[0018] Anhydrous sodium sulfate (sodium sulfate anhydrous, Na2SO4, 142.04 g / mol, CAS number: 7757-82-6) is a sodium sulfate salt and is a colorless crystal. Anhydrous sodium sulfate binds to 10 external water molecules and becomes sodium sulfate (Na2SO4·10H2O; 322.20 g / mol), so it can play a hygroscopic role in a wet environment.
[0019] The composition for improving the stability of bacteriophage may further comprise an excipient component, or may be used as an excipient.
[0020] Excipients may refer to substances added to make feed, food or medicine easy to eat or to make them into a certain shape. As types of excipients, there are adhesives that help molding by giving powder raw materials binding force, disintegrants that promote disintegration, lubricants added to ensure smooth compression operation and good fluidity of granular products, adsorbents that absorb liquid raw materials and make them into tablets (pills), etc. At least one selected from the following group of excipient components can be described as the main excipient component: hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), lactose (water, anhydrous, monohydrate, spray-dried form, etc.), microcrystalline cellulose, titanium dioxide, silicon dioxide (colloidal, colloidal silicon dioxide, etc.), magnesium stearate, cross-linked carboxymethyl cellulose sodium, α-starch (pregelatinized starch), sodium starch glycolate, cross-linked polyvinylpyrrolidone (crosspovidone), talc, wheat flour (cereal powder, wheat powder), calcium carbonate, silicon dioxide, etc., but are not limited to this. The composition for improving the stability of the bacteriophage provided in the present application may further comprise at least one excipient component other than anhydrous sodium sulfate.
[0021] The ratio of anhydrous sodium sulfate contained in the composition for improving the stability of bacteriophage may be 1 to 50% (w / w), 1 to 45% (w / w), 1 to 40% (w / w), 1 to 35% (w / w), 1 to 30% (w / w), 5 to 50% (w / w), 5 to 45% (w / w), 5 to 40% (w / w), 5 to 35% (w / w), 5 to 30% (w / w), 10 to 50% (w / w), 10 to 45% (w / w), 10 to 40% (w / w), 10 to 35% (w / w), 10 to 30% (w / w), 15 to 5 ... 45% (w / w), 15 to 40% (w / w), 15 to 35% (w / w), 15 to 30% (w / w), 20 to 50% (w / w), 20 to 45% (w / w), 20 to 40% (w / w), 20 to 35% (w / w), 20 to 30% (w / w), 25 to 50% (w / w), 25 to 45% (w / w), 25 to 40% (w / w), 25 to 35% (w / w), 25 to 30% (w / w), 30 to 50% (w / w), 30 to 45% (w / w), 30 to 40% (w / w) or 30 to 35% (w / w), etc., but are not limited to these.
[0022] In the present specification, the term "improving the stability of phage" may maintain, improve or enhance the long-term storage stability of phage. In other words, the effect of improving the stability of phage may refer to the effect of maintaining the titer of phage or reducing the amount of titer reduction.
[0023] Bacteriophage is a general term for viruses that use bacteria and archaea as hosts and can specifically infect bacteria. Therefore, in the case of using the antibiotic effect of bacteriophage, it is used in products such as feed (including feed additives), food, medicine, disinfectant, etc., but depending on the production or distribution of the product, there is a problem of reduced productivity and quality of the product due to the reduction in titer of bacteriophage during storage. In other words, the effect of improving the stability of bacteriophage may refer to maintaining the titer of bacteriophage during storage of products containing such bacteriophage, or reducing the amount of reduction in titer of bacteriophage.
[0024] In one embodiment, when the composition for improving the stability of bacteriophage is applied to bacteriophage (e.g., mixed, etc.), when the bacteriophage is stored at a temperature of 45 to 60° C., 45 to 58° C., 45 to 55° C., 45 to 52° C., 45 to 50° C., 45 to 48° C., 48 to 60° C., 48 to 58° C., 48 to 55° C., 48 to 52° C., 48 to 50° C., 50 to 60° C., 50 to 58° C., 50 to 55° C. or 50 to 52° C.; and / or
[0025] at a relative humidity of 80 to 100%, 80 to 99%, 80 to 98%, 80 to 97%, 80 to 96%, 80 to 95%, 80 to 92%, 80 to 90%, 80 to 88%, 80 to 85%, 85 to 100%, 85 to 99%, 85 to 98%, 85 to 97%, 85 to 96%, 85 to 95%, 85 to 92%, 85 to 90%, 85 to 88%, 90 to 100%, 90 to 99%, 90 to 98%, 90 to 97%, 90 to 96%, 90 to 95%, 90 to 92%, 95 to 100%, 95 to 99%, 95 to 98%, 95 to 97% or 95 to 96%,
[0026] The titer of phage measured on day 1 to day 7, day 1 to day 14, day 7 to day 14, after day 1, after day 2, after day 3, after day 4, after day 5, after day 6, after day 7, after day 8, after day 9, after day 10, after day 11, after day 12, after day 13, or after day 14 may be reduced by 2 log (pfu / g) or less, 1.9 log (pfu / g) or less, 1.8 log (pfu / g) or less, 1.7 log (pfu / g) or less, 1.6 log (pfu / g) or less, 1.5 log (pfu / g) or less, or 1.4 log (pfu / g) or less, such as 1.4 log (pfu / g), compared to the titer of phage measured on day 0.
[0027] The reduction may be 20% or less, 19% or less, 18% or less, 17% or less, 16% or less, or 15% or less.
[0028] In another embodiment, when the composition for improving the stability of bacteriophage is applied to bacteriophage (e.g., mixed, etc.), compared to a control group (e.g., a case where anhydrous sodium sulfate is not applied to bacteriophage),
[0029] When the phage is stored at a temperature of 45 to 60°C, 45 to 58°C, 45 to 55°C, 45 to 52°C, 45 to 50°C, 45 to 48°C, 48 to 60°C, 48 to 58°C, 48 to 55°C, 48 to 52°C, 48 to 50°C, 50 to 60°C, 50 to 58°C, 50 to 55°C or 50 to 52°C; and / or
[0030] at a relative humidity of 80 to 100%, 80 to 99%, 80 to 98%, 80 to 97%, 80 to 96%, 80 to 95%, 80 to 92%, 80 to 90%, 80 to 88%, 80 to 85%, 85 to 100%, 85 to 99%, 85 to 98%, 85 to 97%, 85 to 96%, 85 to 95%, 85 to 92%, 85 to 90%, 85 to 88%, 90 to 100%, 90 to 99%, 90 to 98%, 90 to 97%, 90 to 96%, 90 to 95%, 90 to 92%, 95 to 100%, 95 to 99%, 95 to 98%, 95 to 97% or 95 to 96%,
[0031] The reduction in the titer (log(pfu / g)) of the phage measured on day 1 to day 7, day 1 to day 14, day 7 to day 14, after day 1, after day 2, after day 3, after day 4, after day 5, after day 6, after day 7, after day 8, after day 9, after day 10, after day 11, after day 12, after day 13, or after day 14, compared to the titer of the phage measured on day 0, can be as low as 0.5 to 3, 0.5 to 2.5, 0.5 to 2, 0.5 to 1.5, 0.5 to 3, 0.5 to 2.5, 0.5 to 2, 0.5 to 1.5, 0.5 to 2.5, 0.5 to 3.5, 0.5 to 2.5, 0.5 to 1 ...1.5, 0.5 to 2.5, 0.5 to 1.5, 0.5 to 2.5 0.6 to 3, 0.6 to 2.5, 0.6 to 2, 0.6 to 1.5, 0.7 to 3, 0.7 to 2.5, 0.7 to 2, 0.7 to 1.5, 0.8 to 3, 0.8 to 2.5, 0.8 to 2, 0.8 to 1.5, 0.9 to 3, 0.9 to 2.5, 0.9 to 2, 0.9 to 1.5, 1 to 3, 1 to 2.5, 1 to 2, 1 to 1.5, 0.5 or more, 0.6 or more, 0.7 or more, 0.8 or more, 0.9 or more, 1.0 or more, or 1.1 or more, e.g., 1.1 or more.
[0032] It may be as low as 5 to 20% p, 5 to 15% p, 6 to 20% p, 6 to 15% p, 7 to 20% p, 7 to 15% p, 8 to 20% p, 8 to 15% p, 9 to 20% p, 9 to 15% p, 10 to 20% p, 10 to 15% p, 5% p or more, 6% p or more, 7% p or more, 8% p or more, 9% p or more, 10% p or more, or 11% p or more, for example 11% p.
[0033] In other embodiments, when the composition for improving the stability of bacteriophage is applied to the bacteriophage (e.g., mixed, etc.), compared to the control group (e.g., the case where anhydrous sodium sulfate is not applied to the bacteriophage),
[0034] When the phage is stored at a temperature of 45 to 60°C, 45 to 58°C, 45 to 55°C, 45 to 52°C, 45 to 50°C, 45 to 48°C, 48 to 60°C, 48 to 58°C, 48 to 55°C, 48 to 52°C, 48 to 50°C, 50 to 60°C, 50 to 58°C, 50 to 55°C or 50 to 52°C; and / or
[0035] between 80 and 100%, 80 and 99%, 80 and 98%, 80 and 97%, 80 and 96%, 80 and 95%, 80 and 92%, 80 and 90%, 80 and 88%, 80 and 85%, 85 and 100%, 85 and 99%, 85 and 98%, 85 and 97%, 85 and 96%, 85 and 95%, 85 and 92%, 85 and 90%, 85 and 88%, 90 and 100%, 90 and 99%. 9%, 90 to 98%, 90 to 97%, 90 to 96%, 90 to 95%, 90 to 92%, 95 to 100%, 95 to 99%, 95 to 98%, 95 to 97% or 95 to 96% relative humidity for 1 day to 7 days, 1 day to 14 days, 7 days to 14 days, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days or 14 days,
[0036] The titer of the phage can be as high as 2 to 40%, 2 to 35%, 2 to 30%, 2 to 25%, 2 to 20%, 2 to 15%, 2 to 10%, 5 to 40%, 5 to 35%, 5 to 30%, 5 to 25%, 5 to 20%, 5 to 15%, 5 to 10%, 10 to 40%, 10 to 35%, 10 to 30%, 10 to 25%, 10 to 20%, 10 to 15%, 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 11% or more, 12% or more, 13% or more, 14% or more, or 15% or more.
[0037] When the composition for improving the stability of phage is applied to phage, the titer reduction of phage is low even during long-term storage of phage under extreme environments such as high temperature and humid conditions, so there is an advantage that phage can be stably stored.
[0038] The composition for improving the stability of bacteriophages may have an excellent effect of improving the stability of bacteriophages by including anhydrous sodium sulfate, compared to a composition not including anhydrous sodium sulfate.
[0039] The composition for improving the stability of bacteriophage can be used to prepare a feed composition, a food composition, a pharmaceutical composition or an antibacterial composition, etc.
[0040] On the other hand, a composition comprising bacteriophage and anhydrous sodium sulfate is provided, such as a feed composition, a food composition, a pharmaceutical composition, or an antibacterial composition. In addition, a composition comprising bacteriophage and a composition for improving the stability of bacteriophage is provided, such as a feed composition, a food composition, a pharmaceutical composition, or an antibacterial composition.
[0041] As the bacteriophage, the type and number of the bacteriophage are not particularly limited, and any items can be used, and one or more (for example, a combination of 2 types or 3 types) of phages belonging to the Myoviridae, Siphoviridae, and Podoviridae families can be selected and used.
[0042] The bacteriophage may be a phage that specifically infects bacteria belonging to the following genera: Escherichia (e.g., Escherichia coli, Escherichia albertii, Escherichia fergusonii, Escherichia hermannii, Escherichia vulneris, etc.), Salmonella (e.g., Salmonella bongori, Salmonella enterica, etc.), or Clostridium (e.g., Clostridium botulinum, Clostridium tetani, Clostridium perfringens, Clostridium histolyticum, Clostridium sordellii, Clostridium butyricum, etc.), but is not limited thereto.
[0043] The initial content (or titer) of the bacteriophage contained in the composition (e.g., feed composition, food composition, pharmaceutical composition, or antibacterial composition, etc.) is not particularly limited, but it can generally be in the range of 1×10 1 Up to 1×10 15 In addition, the amount of the bacteriophage and anhydrous sodium sulfate (or the composition for improving the stability of the bacteriophage) contained in the composition can be appropriately determined by those skilled in the art in consideration of the purpose of use of the finally prepared composition (e.g., a feed composition, a food composition, a pharmaceutical composition, or an antibacterial composition, etc.).
[0044] In a composition (e.g., a feed composition, a food composition, a pharmaceutical composition, or an antibacterial composition, etc.), the ratio of the composition for improving the stability of bacteriophages in the bacteriophages and the composition for improving the stability of bacteriophages may be 90 to 99.9% (w / w), 90 to 99.5% (w / w), 90 to 99% (w / w), 90 to 98% (w / w), 90 to 97% (w / w), 90 to 96% (w / w), or 90 to 99.9% (w / w). % (w / w), 90 to 95% (w / w), 91 to 99.9% (w / w), 91 to 99.5% (w / w), 91 to 99% (w / w), 91 to 98% (w / w), 91 to 97% (w / w), 91 to 96% (w / w), 91 to 95% (w / w), 92 to 99.9% (w / w), 92 to 99.5% (w / w), 92 to 99% (w / w), 92 to 9 8% (w / w), 92 to 97% (w / w), 92 to 96% (w / w), 92 to 95% (w / w), 93 to 99.9% (w / w), 93 to 99.5% (w / w), 93 to 99% (w / w), 93 to 98% (w / w), 93 to 97% (w / w), 93 to 96% (w / w), 93 to 95% (w / w), 94 to 99.9% (w / w), 94 to 99 .5% (w / w), 94 to 99% (w / w), 94 to 98% (w / w), 94 to 97% (w / w), 94 to 96% (w / w), 94 to 95% (w / w), 95 to 99.9% (w / w), 95 to 99.5% (w / w), 95 to 99% (w / w), 95 to 98% (w / w), 95 to 97% (w / w) or 95 to 96% (w / w), but are not limited thereto.
[0045] In a composition (e.g., a feed composition, a food composition, a pharmaceutical composition, or an antibacterial composition, etc.), the mixing ratio of the bacteriophage to the composition for improving the stability of the bacteriophage may be 1:8 to 1:999, 1:8 to 5:995, 1:8 to 1:99, 1:8 to 2:98, 1:8 to 3:97, 1:88 to 4:96, 1:8 to 5:95, 1:9 to 1:999, 1:9 to 5:995, 1:9 to 1:99, 1:9 to 2:98, 1:9 to 3:97, 1:9 to 4:96, 1:9 to 5:95, etc., by weight, but is not limited thereto.
[0046] In a composition (e.g., a feed composition, a food composition, a pharmaceutical composition, or an antibacterial composition, etc.), the ratio of anhydrous sodium sulfate in the bacteriophage and the composition for improving the stability of the bacteriophage may be 4 to 45% (w / w), 4 to 40% (w / w), 4 to 30% (w / w), 4 to 20% (w / w), 4 to 18% (w / w), 4 to 15% (w / w), 4 to 10% (w / w), 4 to 5% (w / w), 4 to 4.5% (w / w), 4.5 to 45% (w / w), 4.5 to 40% (w / w), 4.5 to 30% (w / w), 4.5 to 20% (w / w), 4.5 to 18% (w / w), 4 to 15% (w / w), 4 to 10% (w / w), 4 to 5% (w / w), 4 to 4.5% (w / w), 4.5 to 45% (w / w), 4.5 to 40% (w / w), 4.5 to 30% (w / w), 4.5 to 20% (w / w), 4.5 to 18% (w / w). % (w / w), 4.5 to 15% (w / w), 4.5 to 10% (w / w), 4.5 to 5% (w / w), 15 to 45% (w / w), 15 to 40% (w / w), 15 to 30% (w / w), 15 to 20% (w / w), 15 to 18% (w / w), 18 to 45% (w / w), 18 to 40% (w / w), 18 to 30% (w / w), 18 to 20% (w / w), 20 to 45% (w / w), 20 to 40% (w / w), 20 to 30% (w / w), 30 to 45% (w / w), 30 to 40% (w / w) or 40 to 45% (w / w), etc., but are not limited thereto.
[0047] In one embodiment, when a composition comprising bacteriophage and anhydrous sodium sulfate or a composition for improving the stability of bacteriophage, such as a feed composition, a food composition, a pharmaceutical composition or an antibacterial composition,
[0048] stored at 45 to 60°C, 45 to 58°C, 45 to 55°C, 45 to 52°C, 45 to 50°C, 45 to 48°C, 48 to 60°C, 48 to 58°C, 48 to 55°C, 48 to 52°C, 48 to 50°C, 50 to 60°C, 50 to 58°C, 50 to 55°C or 50 to 52°C; and / or
[0049] at a relative humidity of 80 to 100%, 80 to 99%, 80 to 98%, 80 to 97%, 80 to 96%, 80 to 95%, 80 to 92%, 80 to 90%, 80 to 88%, 80 to 85%, 85 to 100%, 85 to 99%, 85 to 98%, 85 to 97%, 85 to 96%, 85 to 95%, 85 to 92%, 85 to 90%, 85 to 88%, 90 to 100%, 90 to 99%, 90 to 98%, 90 to 97%, 90 to 96%, 90 to 95%, 90 to 92%, 95 to 100%, 95 to 99%, 95 to 98%, 95 to 97% or 95 to 96%,
[0050] The titer of phage measured on day 1 to day 7, day 1 to day 14, day 7 to day 14, after day 1, after day 2, after day 3, after day 4, after day 5, after day 6, after day 7, after day 8, after day 9, after day 10, after day 11, after day 12, after day 13, or after day 14 may be reduced by 2 log (pfu / g) or less, 1.9 log (pfu / g) or less, 1.8 log (pfu / g) or less, 1.7 log (pfu / g) or less, 1.6 log (pfu / g) or less, 1.5 log (pfu / g) or less, or 1.4 log (pfu / g) or less, such as 1.4 log (pfu / g), compared to the titer of phage measured on day 0.
[0051] The reduction may be 20% or less, 19% or less, 18% or less, 17% or less, 16% or less, or 15% or less.
[0052] In one embodiment, when a composition comprising bacteriophage and anhydrous sodium sulfate or a composition for improving the stability of bacteriophage, such as a feed composition, a food composition, a pharmaceutical composition or an antibacterial composition,
[0053] stored at 45 to 60°C, 45 to 58°C, 45 to 55°C, 45 to 52°C, 45 to 50°C, 45 to 48°C, 48 to 60°C, 48 to 58°C, 48 to 55°C, 48 to 52°C, 48 to 50°C, 50 to 60°C, 50 to 58°C, 50 to 55°C or 50 to 52°C; and / or
[0054] at a relative humidity of 80 to 100%, 80 to 99%, 80 to 98%, 80 to 97%, 80 to 96%, 80 to 95%, 80 to 92%, 80 to 90%, 80 to 88%, 80 to 85%, 85 to 100%, 85 to 99%, 85 to 98%, 85 to 97%, 85 to 96%, 85 to 95%, 85 to 92%, 85 to 90%, 85 to 88%, 90 to 100%, 90 to 99%, 90 to 98%, 90 to 97%, 90 to 96%, 90 to 95%, 90 to 92%, 95 to 100%, 95 to 99%, 95 to 98%, 95 to 97% or 95 to 96%,
[0055] The reduction in the titer of phage measured on day 1 to day 7, day 1 to day 14, day 7 to day 14, after day 1, after day 2, after day 3, after day 4, after day 5, after day 6, after day 7, after day 8, after day 9, after day 10, after day 11, after day 12, after day 13, or after day 14, compared to the titer of phage measured on day 0, can be as low as 0.5 to 3, 0.5 to 2.5, 0.5 to 2, 0.5 to 1.5, 0.6 to 3, 0.7 to 4, 0.8 to 5, 0.9 to 6, 10 to 11, 12 to 13, 14 to 15, 16 to 17, 18 to 19, 20 to 21, 22 to 23, 24 to 25, 26 to 27, 28 to 29, 29 to 30, 30 to 31, 31 to 32, 32 to 33, 33 to 34, 34 to 35 0.6 to 2.5, 0.6 to 2, 0.6 to 1.5, 0.7 to 3, 0.7 to 2.5, 0.7 to 2, 0.7 to 1.5, 0.8 to 3, 0.8 to 2.5, 0.8 to 2, 0.8 to 1.5, 0.9 to 3, 0.9 to 2.5, 0.9 to 2, 0.9 to 1.5, 1 to 3, 1 to 2.5, 1 to 2, 1 to 1.5, 0.5 or more, 0.6 or more, 0.7 or more, 0.8 or more, 0.9 or more, 1.0 or more, or 1.1 or more, e.g., 1.1, or
[0056] It may be as low as 5 to 20% p, 5 to 15% p, 6 to 20% p, 6 to 15% p, 7 to 20% p, 7 to 15% p, 8 to 20% p, 8 to 15% p, 9 to 20% p, 9 to 15% p, 10 to 20% p, 10 to 15% p, 5% p or more, 6% p or more, 7% p or more, 8% p or more, 9% p or more, 10% p or more, or 11% p or more, for example 11% p.
[0057] In one embodiment, when a composition comprising bacteriophage and anhydrous sodium sulfate or a composition for improving the stability of bacteriophage, such as a feed composition, a food composition, a pharmaceutical composition or an antibacterial composition,
[0058] stored at 45 to 60°C, 45 to 58°C, 45 to 55°C, 45 to 52°C, 45 to 50°C, 45 to 48°C, 48 to 60°C, 48 to 58°C, 48 to 55°C, 48 to 52°C, 48 to 50°C, 50 to 60°C, 50 to 58°C, 50 to 55°C or 50 to 52°C; and / or
[0059] between 80 and 100%, 80 and 99%, 80 and 98%, 80 and 97%, 80 and 96%, 80 and 95%, 80 and 92%, 80 and 90%, 80 and 88%, 80 and 85%, 85 and 100%, 85 and 99%, 85 and 98%, 85 and 97%, 85 and 96%, 85 and 95%, 85 and 92%, 85 and 90%, 85 and 88%, 90 and 100%, 90 and 99%. 9%, 90 to 98%, 90 to 97%, 90 to 96%, 90 to 95%, 90 to 92%, 95 to 100%, 95 to 99%, 95 to 98%, 95 to 97% or 95 to 96% relative humidity for 1 day to 7 days, 1 day to 14 days, 7 days to 14 days, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days or 14 days,
[0060] Compared to a composition not comprising anhydrous sodium sulfate,
[0061] The titer of the phage can be as high as 2 to 40%, 2 to 35%, 2 to 30%, 2 to 25%, 2 to 20%, 2 to 15%, 2 to 10%, 5 to 40%, 5 to 35%, 5 to 30%, 5 to 25%, 5 to 20%, 5 to 15%, 5 to 10%, 10 to 40%, 10 to 35%, 10 to 30%, 10 to 25%, 10 to 20%, 10 to 15%, 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 11% or more, 12% or more, 13% or more, 14% or more, or 15% or more.
[0062] When a composition comprising bacteriophage and anhydrous sodium sulfate or a composition for improving the stability of bacteriophage (e.g., a feed composition, a food composition, a pharmaceutical composition, an antibacterial composition, etc.) is placed under extreme environments such as high temperature and humid conditions, it has a lower titer reduction of bacteriophage even during long-term storage of bacteriophage, thus having the advantage of being able to stably store bacteriophage.
[0063] Therefore, the composition comprising bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage) can be prepared in various forms to meet specific purposes in household, industrial, medical and environmental fields, and in one embodiment, it can be prepared in the form of a feed composition (including a feed additive composition), a food composition, a pharmaceutical composition or an antibacterial composition, etc., but is not limited thereto.
[0064] Other aspects provide a feed composition comprising bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage).
[0065] In the present application, "feed" may refer to any natural or artificial diet, one meal, etc. or component of a meal consumed, ingested and digested by an animal or suitable for use therein. The feed composition according to one embodiment may further comprise a concentrate feed and / or a special feed. Concentrated feeds may be seeds and fruits, including cereals such as wheat, oats, corn, etc.; brans, including rice bran, wheat bran, barley bran, etc., as by-products obtained from refining cereals; sesame residues, which are by-products obtained from oil extraction from soybeans, fluid, sesame seeds, flax seeds, coco palm, etc.; and residues, such as residual starch, which is the main component of starch residues remaining after removing starch from sweet potatoes and potatoes, etc.; fish solubles, which are concentrated products of fresh liquid obtained from fish meal, fish residues and fish; animal feeds, such as meat meal, blood meal, feather meal, skim milk powder; dehydrated whey, which is the residual liquid when cheese is made from milk and casein is made from skim milk, etc.; yeast, chlorella and / or seaweed, etc.
[0066] According to one embodiment, the feed composition may refer to a feed in the form of a dietary supplement and / or feed additive that is ultimately eaten by an animal and can be mixed in a feed. A dietary supplement is, for example, a composition containing a preparation that provides a therapeutic agent or a digestive agent to an animal, and is generally not a source of calorie intake in the living body, i.e., a source of energy but a composition ingested in addition to normal animal feed. Feed additives may refer to substances added to feed for various effects, such as nutritional supplements and weight loss prevention, improvement of the digestibility of fiber in feed, improvement of oil quality, prevention of regenerative disorders and improvement of the proportion of conception, prevention of high temperature stress in summer, etc. The feed to which feed additives can be added may be selected from the group consisting of: commercially available feed, or cereals, root fruits (root fruit), food processing byproducts, algae, fiber, drug byproducts, oil and fat, starch, meal (meal), cereal byproducts, protein, inorganic matter, minerals, single cell protein, zooplankton, residual food, etc., but are not limited thereto.
[0067] In one embodiment, the feed composition may be a feed additive, and when the feed additive is mixed into a feed (e.g., a mixed feed and / or a formulated feed ultimately ingested by an animal) according to one embodiment, it may be 0.001% or more, 0.005% or more, 0.01% or more, 0.05% or more, 0.1% or more, 0.5% or more, 1% or less, 0.5% or less, 0.1% or less, 0.05% or less, 0.01% or less, 0.005% or less, 0.001 to 1%, 0.001 to 0.5%, 0.001 to 0.1%, 0.001 to 0.05% by weight of the total feed. , 0.001 to 0.01%, 0.001 to 0.005%, 0.005 to 1%, 0.005 to 0.5%, 0.005 to 0.1%, 0.005 to 0.05%, 0.005 to 0.01%, 0.01 to 1%, 0.01 to 0.5%, 0.01 to 0.1%, 0.01 to 0.05%, 0.05 to 1%, 0.05 to 0.5%, 0.05 to 0.1%, 0.1 to 1%, 0.1 to 0.5% or 0.5 to 1% by weight, and it can be mixed with feed raw materials, complementary feed, supplements and / or other types of additives other than the active ingredient according to one embodiment.
[0068] By mixing bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage) and supplying them to the feed, bacteria in the feed can be reduced or removed.
[0069] Other aspects provide a method for preparing a feed composition, comprising mixing bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage). The feed composition is as described above.
[0070] Other aspects provide a food composition comprising bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage). Bacteriophage specifically kills bacteria, so it can be used to treat processed food or non-processed food or food ingredients to prevent bacterial infection. According to a food composition of an embodiment, it can refer to meat, sausage, bread, chocolate, candy, dessert, cake candy, pizza, ramen, other noodles, chewing gum, dairy products (including ice cream), various types of soup, beverage, tea, beverage, alcoholic beverage, vitamin complex, health functional food and health food, etc., and include all foods in the conventional sense.
[0071] By mixing bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage) and supplying to food, bacteria in food can be reduced or removed.
[0072] Other aspects provide a method for preparing a food composition, comprising mixing bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage). The food composition is as described above.
[0073] Other aspects provide a pharmaceutical composition for preventing or treating bacterial infection of Escherichia, Salmonella or Clostridium or diseases caused by bacteria of the genus Escherichia, Salmonella or Clostridium, which comprises a bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of the bacteriophage). Other embodiments provide a method for preventing or treating bacterial infection of Escherichia, Salmonella or Clostridium or diseases caused by bacteria of the genus Escherichia, Salmonella or Clostridium, which comprises administering a pharmaceutically effective dose of a bacteriophage and a composition for improving the stability of the bacteriophage to a subject who needs to prevent or treat bacterial infection of Escherichia, Salmonella or Clostridium or diseases caused by bacteria of the genus Escherichia, Salmonella or Clostridium. The bacteriophage specifically kills bacteria (e.g., bacteria of the genus Escherichia, Salmonella or Clostridium), so it can be effectively used to prevent or treat diseases caused by the bacteria.
[0074] The Escherichia bacteria may be Escherichia coli, Escherichia albertii, Escherichia fergusonii, Escherichia hermannii or Escherichia wounds, etc., the Salmonella bacteria may be Salmonella bongori or Salmonella enterica, etc., and the Clostridium bacteria may be Clostridium botulinum, Clostridium tetani, Clostridium perfringens, Clostridium histolyticum, Clostridium sordellii or Clostridium butyricum, etc., but are not limited thereto.
[0075] The infection with Escherichia bacteria or the disease caused by it may be enteritis, Crohn's disease, ulcerative colitis, bacterial dysentery, urinary tract infection, skin infection, bacteremia or sepsis, etc. The infection with Salmonella bacteria or the disease caused by it may be salmonellosis, Salmonella food poisoning, etc. The infection with Clostridium bacteria or the disease caused by it may be botulism food poisoning, Clostridium perfringens food poisoning, Clostridium difficile-induced colitis, Clostridium necrotizing enterocolitis, neutropenic enterocolitis or neonatal necrotizing enterocolitis, but are not limited to these.
[0076] The pharmaceutical composition according to one embodiment may further include a suitable carrier, excipient or diluent commonly used to prepare the pharmaceutical composition. Specifically, the pharmaceutical composition can be prepared and used in the form of oral preparations (such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc.), external preparations, suppositories and sterile injection solutions according to common methods.
[0077] According to one embodiment, the pharmaceutical composition can be administered at a pharmaceutically effective dose, and in the present application, "pharmaceutically effective dose" refers to an amount sufficient to treat or prevent a disease at a reasonable benefit / risk ratio suitable for medical treatment or prevention, and the effective dose level can be determined based on factors including: disease severity; drug activity; patient's age, weight, health, gender; patient's sensitivity to the drug; administration time; route of administration and excretion rate of the composition used in the present application; treatment period; drugs used in combination or simultaneously with the composition used in the present application, and other factors well known in the medical field. According to one embodiment, the pharmaceutical composition can be administered as a single therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents. In addition, it can be administered once or multiple times. Taking all the above factors into account, it is crucial to administer an amount that can achieve the maximum effect with the minimum amount without side effects.
[0078] The dosage of the pharmaceutical composition according to one embodiment may be 0.0001 to 10,000 mg / g, 0.0001 to 5,000 mg / g, 0.0001 to 1,000 mg / g, 0.0001 to 500 mg / g, 0.0001 to 100 mg / g, 0.0001 to 50 mg / g or 0.0001 to 10 mg / g administered to a mammal every day, but is not limited thereto. The frequency of administration of the pharmaceutical composition of the present application is not subject to other specific restrictions, but it can be administered once a day, or several times by dividing the dose. The dosage is not intended to limit the scope of the application in any way.
[0079] The subject of administration of the pharmaceutical composition provided in this specification may be a mammal, including humans, dogs, cats, horses, pigs, goats, rabbits, mice, rats, etc., or cells, tissues or cultures thereof isolated therefrom, and in one embodiment, the subject may be a subject (mammal, such as humans, etc.) or cells, tissues or cultures thereof isolated therefrom that need to prevent, improve and / or treat the disease as described above. The disease may be an infection of Escherichia coli, Salmonella or Clostridium bacteria, or a disease caused by Escherichia coli, Salmonella or Clostridium bacteria.
[0080] Other aspects provide a method for preparing a pharmaceutical composition, comprising mixing bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage).
[0081] Other aspects provide an antibacterial composition comprising a bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of a bacteriophage).
[0082] In this specification, antibacterial activity may refer to the activity of inhibiting and / or killing bacterial growth, etc., and the antibacterial composition may refer to a composition having antibacterial activity. Antibacterial activity may be used in combination with antibiotic activity, etc., and the antibacterial composition covers all types of preparations capable of inhibiting bacterial growth and / or capable of killing bacterial growth, and unless otherwise mentioned, it can be used interchangeably with antibacterial agents, antibiotics, preservatives, bactericides, disinfectants, etc.
[0083] In one embodiment, the antibacterial composition refers to a preparation for preventing bacterial infection, and can be used as a general life disinfectant, a disinfectant for food and cooking places and facilities, and a disinfectant for various growth products (such as buildings including chicken farms and barns, livestock, drinking water, garbage, egg beds, transport vehicles, tableware, etc.). The bacteria may be Escherichia coli, Salmonella, or Clostridium, but are not limited thereto.
[0084] Other aspects provide a method for preparing an antibacterial composition, which comprises mixing bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage). The antibacterial composition is as described above.
[0085] Other aspects provide a method for improving bacterial stability, comprising mixing bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage). The bacteriophage or the stability improvement of bacteriophage is as described above.
[0086] Other aspects provide an antibacterial method, comprising the step of applying bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage) to a subject in need of antibacterial treatment. The antibacterial method may be a method for controlling bacteria (a method for controlling bacteria), a method for reducing bacteria (a method for reducing bacteria), a method for inhibiting bacteria (e.g., a method for inhibiting bacterial growth, etc.), or a method for killing bacteria, etc., but is not limited thereto.
[0087] Other aspects provide a washing method comprising the step of applying bacteriophage and anhydrous sodium sulfate (or a composition for improving the stability of bacteriophage) to a subject in need of washing.
[0088] Other aspects provide a use of anhydrous sodium sulfate for improving the stability of bacteriophages or for preparing a composition for improving the stability of bacteriophages.
[0089] Other aspects provide a use of a bacteriophage and anhydrous sodium sulfate for preparing a feed composition, a food composition, a pharmaceutical composition or an antibacterial composition.
[0090] Other aspects provide a use of a bacteriophage and a composition for improving the stability of a bacteriophage for preparing a feed composition, a food composition, a pharmaceutical composition or an antibacterial composition.
[0091] Beneficial Effects
[0092] The present application can improve the storage stability of bacteriophages by using a composition comprising anhydrous sodium sulfate for improving the stability of bacteriophages. BRIEF DESCRIPTION OF THE DRAWINGS
[0093] Figure 1 Shown is a graph of measuring the titer of phages on day 0, day 7, and day 14 after storing phage samples (4 g of 5 mixed phages and an excipient not including anhydrous sodium sulfate) under conditions of 50±2°C, 90±5% RH.
[0094] Figure 2 A graph showing the titer of phages measured on day 0, day 7, and day 14 after storing phage samples (4 g of 5 mixed phages and an excipient containing anhydrous sodium sulfate 20% (w / w)) under conditions of 50±2°C, 90±5% RH.
[0095] Figure 3 A graph showing the titer of phages measured on day 0, day 7, and day 14 after storing phage samples (4 g of 5 mixed phages and an excipient containing anhydrous sodium sulfate 50% (w / w)) under conditions of 50±2°C, 90±5% RH.
[0096] Figure 4 The decrease in the titer of phage (Δlog (pfu / g)) measured on day 0 and day 14 after storing the phage samples under the conditions of 50±2°C, 90±5% RH is shown. As excipients, an excipient not containing anhydrous sodium sulfate, an excipient containing 20% (w / w) of anhydrous sodium sulfate, and an excipient containing 50% (w / w) of anhydrous sodium sulfate were used. DETAILED DESCRIPTION
[0097] Hereinafter, the present invention will be described in more detail by the following examples. However, they are only intended to illustrate the present invention, but the scope of the present invention is not limited by these examples.
[0098] Example 1. Evaluation of the Storage Stability of Anhydrous Sodium Sulfate
[0099] 1. Phage Sample Preparation
[0100] Phage samples 1 to 3 were prepared by mixing 4 g of 5 mixed phages with 36 g of excipients, from 2 bags per sample, as shown in Table 1 below. Sample 1 used an excipient prepared by mixing 90% (w / w) wheat flour (Sajo Dongaone, wheat flour (grade 2, medium 2 class)), 5% (w / w) silicon dioxide (FuJian SanMing Zheng Yuan Chemical, precipitated silicon dioxide, ZJ-516B) and 5% (w / w) calcium carbonate (Omya Korea, calcium carbonate). Samples 2 and 3 used a mixed excipient prepared by mixing an excipient component and anhydrous sodium sulfate, the excipient component being prepared by mixing wheat flour, silicon dioxide and calcium carbonate as described above (conventional excipient). The compositions of samples 1 to 3 are summarized in Table 1 below.
[0101] Five mixed phages were prepared with the following composition:
[0102] CJ7: 6×10 9 PFU / g, CJ11: 4×10 9 PFU / g, CJ23: 1×10 9 PFU / g, CJ24: 5×10 9 PFU / g, CJ22: 3×10 8 PFU / g.
[0103] [Table 1]
[0104]
[0105] The common names of bacteriophages, target strains and sources of acquisition are shown in Table 2:
[0106] [Table 2]
[0107] Experimental Group Common names of bacteriophages Target strains Accession number CJ7 Longicaudophage family Salmonella KCCM11030P CJ11 Longicaudophage family Salmonella KCCM11208P CJ23 Brachyura phagidae Escherichia coli KCCM11365P CJ24 Longicaudophage family Escherichia coli KCCM11462P CJ22 Longicaudophage family Clostridium perfringens KCCM11364P
[0108] 2. Storage conditions
[0109] 40 g of each sample was placed in an aluminum bag and heat-sealed 3 times. Each sample was stored under the conditions of 50±2° C., 90±5% RH (relative humidity).
[0110] 3. Phage titer measurement
[0111] After the samples were stored for 7 and 14 days, each sample was diluted 10-fold in SM buffer (5.8 g / L NaCl, 2 g / LMgSO4·7H2O, 0.05 M Tris-Cl (pH 7.5)) (sample 20 g + SM buffer 180 ml). After centrifugation (10,000 rpm, 10 minutes) of 50 ml of the diluted solution, the phage solution was filtered with a 0.2 μm filter.
[0112] 4. Plaque Assay Titration
[0113] After the phage solution was serially diluted to the appropriate concentration, 100 μl of the phage sample diluted in 5 ml of 0.7% soft agar (BDDIFCO, catalog number 44164) was mixed with 50 μl of the indicator strain of phage (OD 600 nm =2) Mixing.
[0114] After pouring a general LB (Luria-Bertani, aerobic) or brain heart infusion (BHI, Brain Heart Infusion, anaerobic) medium and plating, the number of plaques after culturing in an incubator (aerobic; 30°C, 18 h, anaerobic; 37°C, 18 h) was measured to quantify phages.
[0115] 5. Experimental Results
[0116] The results of quantifying the phage of each sample at 7 and 14 days after sample storage are shown in Figures 1 to 3 And in Tables 2 to 4 (Sample 1: Figure 1 , Table 2; Sample 2: Figure 2 , Table 3; Sample 3: Figure 3 , Table 4). The difference between the titer value on day 0 (log (pfu / g)) and the titer value on day 14 (log (pfu / g)) was expressed as Δlog, and the difference was divided by the titer value on day 0 to describe the titer reduction. Figure 4 In FIG. 1 , the titer reduction (Δlog) of the five phages (CJ7, CJ11, CJ23, CJ24, and CJ22) included in samples 1 to 3 over 14 days after sample storage is shown as a graph.
[0117] [Table 3]
[0118]
[0119] [Table 4]
[0120]
[0121] [Table 5]
[0122]
[0123] As a quantitative result, when a conventional excipient (Sample 1) was used, the five phages (CJ7, CJ11, CJ23, CJ24, CJ22) in the excipient showed an average 2.5 log reduction in phage titer (average reduction of 27.2%) when exposed to 50±2°C, 90±5% RH for 14 days ( Figure 1 , Table 3).
[0124] On the other hand, when a mixed excipient (in which the excipient was mixed with anhydrous sodium sulfate) was used, the five phages in the excipient showed about 1.3 log (an average reduction of 14.2%) (Sample 2, Figure 2 , Table 4) and 1.2log (average reduction of 12.3%) (Sample 3, Figure 3 , Table 5) of the phage titer reduction.
[0125] In other words, when the mixed excipient in which anhydrous sodium sulfate was mixed was used, an effect of maintaining phage stability by an average of 1.3 log was shown compared to the conventional excipient.
[0126] According to the above description, it should be understood by those skilled in the art that the present invention can be implemented in other specific forms without changing its technical spirit or basic features. In this regard, the embodiments described above should be understood to be illustrative and non-restrictive in all aspects. The scope of the present invention should be deemed to include all changes or modifications derived from the meaning and scope of the claims described below and their equivalents rather than the detailed description above.
Claims
1. A composition for improving the stability of bacteriophages, comprising anhydrous sodium sulfate.
2. The composition for improving the stability of bacteriophage according to claim 1, comprising 5 to 50 wt% of anhydrous sodium sulfate.
3. The composition for improving the stability of a bacteriophage according to claim 1, which is used to improve the stability of at least one bacteriophage selected from the group consisting of Myoviridae, Siphoviridae and Podoviridae phages.
4. Use of the composition for improving the stability of bacteriophage according to any one of claims 1 to 3 in the preparation of a feed composition, a food composition or an antibacterial composition.
5. A feed composition comprising a bacteriophage and the composition for improving the stability of the bacteriophage according to any one of claims 1 to 3.
6. The feed composition according to claim 5, wherein The mixing ratio of the bacteriophage contained in the feed composition to the composition for improving the stability of the bacteriophage is 1:9 to 1:99 (above, weight of bacteriophage:weight of the composition for improving the stability of the bacteriophage).
7. The feed composition according to claim 5, wherein The feed composition has the following characteristics: When stored at a temperature of 45 to 60° C. and a relative humidity of 80 to 100% for 1 to 14 days, the titer of the bacteriophage contained in the feed composition is 10% or more higher than that of a feed composition not containing anhydrous sodium sulfate.
8. A food composition comprising a bacteriophage and the composition for improving the stability of a bacteriophage according to any one of claims 1 to 3.
9. The food composition according to claim 8, wherein The mixing ratio of the bacteriophage contained in the food composition to the composition for improving the stability of the bacteriophage is 1:9 to 1:99 (above, weight of bacteriophage:weight of the composition for improving the stability of the bacteriophage).
10. The food composition according to claim 8, wherein The food composition has the following characteristics: When stored at a temperature of 45 to 60° C. and a relative humidity of 80 to 100% for 1 to 14 days, the titer of the bacteriophage contained in the food composition is 10% or more higher than that of a food composition not containing anhydrous sodium sulfate.
11. An antibacterial composition comprising a bacteriophage and the composition for improving the stability of the bacteriophage according to any one of claims 1 to 3.
12. The antibacterial composition according to claim 11, wherein The mixing ratio of the bacteriophage contained in the antibacterial composition to the composition for improving the stability of the bacteriophage is 1:9 to 1:99 (above, weight of bacteriophage:weight of the composition for improving the stability of the bacteriophage).
13. The antibacterial composition according to claim 11, wherein The antibacterial composition has the following characteristics: When stored at a temperature of 45 to 60° C. and a relative humidity of 80 to 100% for 1 to 14 days, the titer of the bacteriophage contained in the antibacterial composition is 10% or more higher than that of an antibacterial composition not containing anhydrous sodium sulfate.
14. A method for improving the stability of a bacteriophage, comprising the step of mixing a bacteriophage and the composition for improving the stability of a bacteriophage according to any one of claims 1 to 3.
15. An antibacterial method comprising the step of administering a bacteriophage and the composition for improving the stability of a bacteriophage according to any one of claims 1 to 3 to a subject in need of antibacterial treatment.
